New study from Denmark shows that use of semaglutide (Wegovy) for weight management is associated with a 7% reduction in triptan-class drugs for migraine treatment, particularly among women.
A nationwide study presented at the European Congress on Obesity in Istanbul, Turkey, has found that initiation of semaglutide (Wegovy), a GLP-1 receptor agonist used for weight management, may lead to an 8% reduction in the use of triptan-class drugs for migraine treatment among women after one year. The study was conducted by Professor Anton Pottegard and Assistant Professor Noémie Roland from the Department of Public Health at the University of Southern Denmark.
The researchers identified all adults who initiated semaglutide for weight management between December 1, 2022, and June 30, 2024, using comprehensive Danish health registers. They compared the monthly use of triptans before and after semaglutide introduction, finding that the trend in DDDs (defined daily doses) per 10,000 individuals changed from an increasing trend to a decreasing one. Specifically, there was a reduction of -14 DDDs/month/10,000 individuals over time.
The study revealed that women showed a significant 8% reduction in triptan use at 12 months post-intervention compared to men, who did not show any notable change. This sex-specific effect may be attributed to greater semaglutide-associated weight loss typically observed in women. Additionally, the largest reductions were seen among individuals aged 18-35 years and those with a history of using prophylactic antimigraine medications.
The researchers suggest that this reduction could be due to several factors, including weight loss and improvements in metabolic health, which may help reduce migraine frequency through reduced inflammatory processes. Furthermore, GLP-1RA treatments might have direct effects on the central nervous system that influence migraine pathways, independent of weight loss.
While the study provides promising insights into the potential benefits of semaglutide for managing migraines, it also highlights the need for further investigation into the underlying biological mechanisms. The authors conclude that initiation of semaglutide is associated with a gradual reduction in triptan use among women during the first year after initiation.
This research underscores the importance of exploring how GLP-1 receptor agonists like semaglutide can impact migraine treatment and offers hope for new therapeutic options for individuals suffering from this common condition.
